Cocrystal Pharma, Inc. (COCP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5M 10M 15M FY11: 12.7M FY19: 6.6M FY20: 2M FY11 FY19 FY20

Gross Profit Annual

0 2.5M 5M 7.5M FY10: 6.8M FY11: 2.7M FY12: 7.2M FY10 FY11 FY12

Operating Income Annual

-120M -80M -40M 0 40M 80M 120M FY10: -32K FY11: -3.9M FY12: -2.6M FY13: -4.1M FY14: -5.8M FY15: -53.9M FY16: -105.8M FY17: -8.3M FY18: -62.9M FY19: -48.4M FY20: -9.6M FY21: -14.2M FY22: -38.8M FY23: -18.6M FY24: -17.9M FY25: -9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY10: -319.8K FY11: -5.5M FY12: -8M FY13: -3.9M FY14: -99K FY15: -50.1M FY16: -74.9M FY17: -613K FY18: -49M FY19: -48.2M FY20: -9.6M FY21: -14.2M FY22: -38.8M FY23: -18M FY24: -17.5M FY25: -8.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150K 300K 450K FY12: 405.9K FY12

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY10: -261.4K FY11: -421K FY12: -1.6M FY13: -3.7M FY14: -6M FY15: -10.3M FY16: -14.7M FY17: -6.9M FY18: -8.3M FY19: -1.6M FY20: -9.8M FY21: -12.7M FY22: -21.4M FY23: -14.7M FY24: -16.5M FY25: -8.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY10: -619K FY11: -996.4K FY12: -1.7M FY13: -3.7M FY14: -6M FY15: -10.7M FY16: -14.7M FY17: -6.9M FY18: -8.3M FY19: -1.7M FY20: -10.1M FY21: -12.8M FY22: -21.5M FY23: -14.8M FY24: -16.5M FY25: -8.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150M 300M 450M FY11: 50.4M FY12: 61.6M FY13: 57.3K FY14: 327.8M FY15: 21M FY16: 23.5M FY17: 24.1M FY18: 28K FY19: 31.9K FY21: 7.4M FY22: 8.1M FY23: 9.7M FY24: 10.2M FY25: 11.3M FY12 FY14 FY16 FY18 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '10: -0.01 Q1 '11: -0.01 Q2 '11: -0.02 Q3 '11: -0.07 Q4 '11: -0.09 Q1 '12: -0.15 Q2 '12: -0.15 Q3 '12: -0.11 Q4 '12: -0.13 Q3 '16: -0.06 Q4 '16: -3.07 Q1 '17: -3.17 Q2 '17: -3.26 Q3 '17: -3.26 Q4 '17: 0.00 Q1 '18: 0.05 Q2 '18: 0.09 Q3 '18: 0.03 Q4 '18: -1.75 Q1 '19: -1.59 Q2 '19: -1.59 Q3 '19: -1.59 Q4 '19: -1.51 Q1 '20: -1.66 Q2 '20: -1.68 Q3 '20: -1.67 Q4 '20: -0.18 Q1 '21: -0.17 Q2 '21: -0.14 Q3 '22: -4.26 Q4 '22: -4.76 Q1 '23: -4.88 Q2 '23: -2.29 Q3 '23: -2.00 Q4 '23: -1.90 Q1 '24: -1.65 Q2 '24: -1.77 Q3 '24: -1.85 Q4 '24: -1.73 Q1 '25: -1.57 Q2 '25: -1.24 Q3 '25: -0.94 Q4 '25: -0.79 Q1 '26: -0.73 Q2 '26: -0.76 Q2 '11 Q4 '12 Q4 '17 Q2 '19 Q4 '20 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.